drugset / Trial / NCT01278108
First-in-Human Single Ascending and Multiple Dose of GLPG0778
RandomizedParallel-groupQuadruple-blind
Summary
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral doses of GLPG0778 compared to placebo (with and without food). Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0778 after single and multiple oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.
Timeline
- Start
- 2010-12
- Primary completion
- 2011-02
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SOLCITINIB | Small molecule | 10 mg | Oral |
| Subject | SOLCITINIB | Small molecule | 100 mg | Oral |
| Subject | SOLCITINIB | Small molecule | 800 mg | Oral |
Indications
No indication recorded.